<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164721</url>
  </required_header>
  <id_info>
    <org_study_id>MADIT-CHIC</org_study_id>
    <nct_id>NCT02164721</nct_id>
  </id_info>
  <brief_title>Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy</brief_title>
  <acronym>MADIT-CHIC</acronym>
  <official_title>Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial or study is to determine if cardiac resynchronization therapy (CRT)
      can be a benefit to people who have impaired heart function due to past treatment with
      chemotherapy and/or chest radiation. The investigators are looking to enroll approximately 30
      eligible subjects with heart failure in this trial. All patients enrolled and registered in
      the study will be implanted with a cardiac resynchronization therapy device that includes an
      implantable cardiac defibrillator (CRT-D). Clinical histories, physical exams, and external
      device testing will be collected both at the time of enrollment in the trial and during
      follow-up study visits. Following implantation of the CRT-D, patients will be contacted by
      phone at 3 months and will have a scheduled clinic visit follow-up at 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the advent of new therapies and an increasing number of long-term cancer survivors, the
      incidence and consequently the interest in chemotherapy-induced cardiomyopathy (CHIC) have
      been increasing. CHIC is a dose-dependent cardiomyopathy and presents as congestive heart
      failure several months to years after the administration of chemotherapy and/or chest
      radiation that includes the heart.

      Greater than one-half of the patients exposed to just this class of drugs will show evidence
      of cardiac dysfunction, with 5% presenting with overt symptomatic heart failure. The overall
      incidence of CHIC is significantly underestimated as within the US alone, greater than 60,000
      patients receive just anthracyclines every year. Despite this, there is little data on their
      response to conventional heart failure therapy. There is some preliminary evidence from two
      small, retrospective case-series suggesting that patients with CHIC and evidence of
      conduction tissue disease (i.e. a wide electrocardiographic depolarization duration (QRS) may
      significantly benefit from cardiac resynchronization therapy (CRT).

      MADIT-CHIC is a multicenter, non-randomized, prospective observational study. The primary aim
      is to determine if CRT-D (Defibrillator) in high-risk patients with chemotherapy-induced
      cardiomyopathy will significantly improve left ventricular ejection fraction (LVEF) by
      echocardiography within 6 months of initiating CRT without adversely affecting mortality.

      The study will last 6 months and will be conducted in 10-15 clinical centers in the United
      States.

      Following implantation of the CRT-D device (Defibrillator), patients will be followed for 6
      months. The first follow-up contact will be by phone at which time study personnel will
      review the patient's health status. The last study contact will be a 6-month clinic visit. At
      the 6-month visit, the patient's health status will be reviewed, the functioning of the CRT-D
      (Defibrillator) will be tested and an echocardiogram will be conducted. After the 6-month
      visit, the study-required follow-up will have been completed and patients will continue to
      have CRT-D (Defibrillator) clinical follow-up based on their physicians direction.

      During the course of the study, Subjects will as outlined in the inclusion criteria continue
      on stable optimal pharmacologic therapy for the cardiac condition that is guideline-based and
      may include one or more of the following medications: Loop diuretics, Angiotensin converting
      enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB), Aldosterone antagonists
      and/or Beta-blockers unless the subject is not indicated, contraindicated, or is intolerant
      of medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">February 6, 2019</completion_date>
  <primary_completion_date type="Actual">February 6, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction</measure>
    <time_frame>6 months post implant</time_frame>
    <description>The primary endpoint will be the change in left ventricular ejection fraction (LVEF) from baseline to six months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-Cause Mortality</measure>
    <time_frame>6 months post implant</time_frame>
    <description>Number of Participants with All-Cause Mortality in CRT-D patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CRT Therapy on Left Ventricular Volume at End Diastole</measure>
    <time_frame>6 months post implant</time_frame>
    <description>Determine based on echocardiogram study if CRT therapy improves left ventricular volume at end diastole (LVEDV) between baseline and six months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CRT Therapy on Left Ventricular Volume at End Systole</measure>
    <time_frame>6 months post implant</time_frame>
    <description>Determine based on echocardiogram study if CRT therapy improves left ventricular volume at end systole (LVESV) between baseline and six months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in New York Heart Association (NYHA) Functional Class</measure>
    <time_frame>6 months post implant</time_frame>
    <description>Improvement in NYHA functional class between baseline and six months (yes/no), ie. change from NYHA class III to NYHA II.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Left Atrial Size</measure>
    <time_frame>6 months post implant</time_frame>
    <description>Change in left atrial size between baseline and six months</description>
  </other_outcome>
  <other_outcome>
    <measure>Effects of CRT on Frequency of Heart Failure</measure>
    <time_frame>6 months post implant</time_frame>
    <description>Effects of CRT on the frequency of heart failure with end point of inpatient hospitalization with augmented treatment for heart failure</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>CRT-D (Defibrillator)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Implantation of a three-lead CRT-D (Defibrillator) in all registered patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Three-lead CRT-D (Defibrillator)</intervention_name>
    <description>The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.</description>
    <arm_group_label>CRT-D (Defibrillator)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 (or of legal age to give informed consent specific to state and national law)
             up to 80 years of age

          -  Male or Female

          -  Without clinical heart failure at initiation of chemotherapy/radiation-induced
             treatment for an underlying malignancy, but developed clinical heart failure
             (cardiomyopathy: reduced left ventricular ejection fraction (LVEF) with a left bundle
             branch block (LBBB)-type of conduction disturbance; see next inclusion item) 6 months
             or more after initiation of the chemotherapy without other evident cause of the
             cardiomyopathy.

          -  Eligible for implantation of a CRT-D (cardiac resynchronization therapy-defibrillator)
             device according to one of the following options in currently available guidelines:

               1. Class 1: Left ventricular ejection fraction (LVEF) less than or equal to 35% AND
                  sinus rhythm AND LBBB (left bundle branch block) with a QRS (electrocardiographic
                  depolarization duration) duration greater than or equal to 150ms AND NYHA (New
                  York Heart Association) class II, III or ambulatory IV symptoms on
                  guideline-directed medical therapy

               2. Class 2a1: Left ventricular ejection fraction (LVEF) less than or equal to 35%
                  AND sinus rhythm AND left bundle branch block (LBBB) with a QRS
                  (electrocardiographic depolarization duration) duration 120-149ms AND New York
                  Heart Classification (NYHA) class II, III or ambulatory IV symptoms on
                  guideline-directed medical therapy

               3. Class 2a2: Left ventricular ejection fraction (LVEF) less than or equal to 35%
                  AND sinus rhythm AND Non-left bundle branch block (LBBB) with a
                  QRS(electrocardiographic depolarization duration) duration greater than or equal
                  to 150ms AND New York Heart Classification (NYHA) class III or ambulatory IV
                  symptoms on guideline-directed medical therapy

          -  On stable optimal pharmacologic therapy for the cardiac condition that is
             guideline-based and may include one or more of the following medications: Loop
             diuretics, Angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor
             blocker (ARB), Aldosterone antagonists and/or Beta-blockers unless the subject is not
             indicated, contraindicated, or is intolerant of medication.

        Exclusion Criteria:

          -  Currently implanted pacemaker or implantable cardioverter defibrillator (ICD) device

          -  Previous implant with a CRT (cardiac resynchronization therapy)/CRT-D (cardiac
             resynchronization therapy-defibrillator) device

          -  Cardiac condition not presumed to be caused by chemotherapy

          -  Documented symptoms or hemodynamically unstable ventricular tachyarrhythmia

          -  On active chemotherapy (must be at least 6 calendar months after last chemotherapy)

          -  Permanent or chronic Atrial Fibrillation (AF), or cardioversion for AF within the past
             3 calendar months before consent date

          -  Structural heart disease such as congenital heart disease, valvular heart disease,
             e.g., rheumatic valvular heart disease, amyloid heart disease, etc.

          -  Coronary artery bypass graft surgery or percutaneous coronary intervention within the
             past 3 calendar months before consent date

          -  Enzyme positive myocardial infarction within the past 3 calendar months prior to
             consent date

          -  Unstable angina requiring hospitalization, with diagnostic work up and intervention
             within the past 3 months prior to consent date

          -  Angiographic evidence of coronary disease who are candidates for coronary
             revascularization and are likely to undergo coronary artery bypass graft surgery or
             percutaneous coronary intervention in the foreseeable future

          -  Class IV and expected to undergo transplant within study duration

          -  Current or past history of drug addiction or abuse that caused cardiomyopathy

          -  Pregnant or plans to become pregnant during the course of the trial.

          -  Recent cerebral vascular accident or transient ischemia attack within the previous 3
             months prior to consent date

          -  Presence of any disease, other than the subject's cardiac or cancer disease,
             associated with a reduced likelihood of survival for the duration of the trial, e.g.,
             uremia, liver failure, active malignant disease, etc.

          -  Participating in any other clinical trial

          -  Unwilling or unable to cooperate with the protocol

          -  Lives at such a distance from the clinic that travel for follow-up visits would be
             unusually difficult

          -  Does not anticipate being a resident of the area for the scheduled duration of the
             trial

          -  Unwilling to sign the consent for participation

          -  Physician does not allow participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentina Kutyifa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Cardiovascular Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospita/Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <results_first_submitted>January 24, 2020</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2020</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Valentina Kutyifa</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Chemotherapy-induced cardiomyopathy</keyword>
  <keyword>Cardiac resynchronization therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02164721/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CRT-D (Defibrillator)</title>
          <description>Implantation of a three-lead Cardiac Resynchronization Therapy -Defibrillator (CRT-D) in all registered patients
Three-lead CRT-D (Defibrillator): The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CRT-D (Defibrillator)</title>
          <description>Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
Three-lead CRT-D (Defibrillator): The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="54" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with Nonischemic cardiomyopathy</title>
          <population>In one patient, the presence of nonischemic cardiomyopathy was unknown.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Electrocardiographic depolarization duration (QRS) after consent</title>
          <units>ms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152" lower_limit="142" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with Left bundle branch block (LBBB) after consent</title>
          <description>Left Bundle Branch Block (LBBB) was ascertained by reviewing ECGs collected at baseline, following informed consent.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinus rhythm after consent</title>
          <description>Number of Participants with Normal Sinus Rhythm at Baseline.
Normal Sinus Rhythm at Baseline was ascertained by reviewing ECGs collected at baseline, following informed consent.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with a History of ventricular arrhythmias</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with a history of atrial arrhythmias</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with Anthracycline history</title>
          <population>One patient had missing data for anthracycline history.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Time since cancer diagnosis</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.8" lower_limit="1.1" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Age at cancer diagnosis</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="40" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with History of breast cancer</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with a History of leukemia or lymphoma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with a History of sarcomas</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median blood urea nitrogen levels</title>
          <population>Data were available in 27 out of 30 participants.</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="15" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Creatinine Levels</title>
          <population>Data were available in 28 out of 30 participants.</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.95" lower_limit="0.85" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association class, II</title>
          <description>Heart failure symptom severity was categorized using the New York Heart Association (NYHA Class) at enrollment, stages below:
I No limitation of physical activity. II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath.
III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or shortness of breath.
IV Unable to carry on any physical activity without discomfort with symptoms at rest.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association class, III</title>
          <description>Heart failure symptom severity was categorized using the New York Heart Association (NYHA Class) at enrollment, stages below:
I No limitation of physical activity. II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath.
III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or shortness of breath.
IV Unable to carry on any physical activity without discomfort with symptoms at rest.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Blood pressure, systolic</title>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121.5" lower_limit="116" upper_limit="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Blood pressure, diastolic</title>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" lower_limit="60" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participant taking a Beta-Blocker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants taking a Loop diuretic</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants taking Aldosterone</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Ventricular Ejection Fraction</title>
        <description>The primary endpoint will be the change in left ventricular ejection fraction (LVEF) from baseline to six months</description>
        <time_frame>6 months post implant</time_frame>
        <population>Change in left ventricular ejection fraction (LVEF) from baseline to six months was analyzed with 26 patients with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D (Defibrillator)</title>
            <description>Implantation of a three-lead CRT-D (Defibrillator) in all registered patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction</title>
          <description>The primary endpoint will be the change in left ventricular ejection fraction (LVEF) from baseline to six months</description>
          <population>Change in left ventricular ejection fraction (LVEF) from baseline to six months was analyzed with 26 patients with data available.</population>
          <units>percentage of LVEF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-Cause Mortality</title>
        <description>Number of Participants with All-Cause Mortality in CRT-D patients</description>
        <time_frame>6 months post implant</time_frame>
        <population>Event rate of all-cause mortality is described.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D (Defibrillator)</title>
            <description>Implantation of a three-lead CRT-D (Defibrillator) in all registered patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-Cause Mortality</title>
          <description>Number of Participants with All-Cause Mortality in CRT-D patients</description>
          <population>Event rate of all-cause mortality is described.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of CRT Therapy on Left Ventricular Volume at End Diastole</title>
        <description>Determine based on echocardiogram study if CRT therapy improves left ventricular volume at end diastole (LVEDV) between baseline and six months</description>
        <time_frame>6 months post implant</time_frame>
        <population>Describe 23 patients with data available on LVEDV change</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D (Defibrillator)</title>
            <description>Implantation of a three-lead CRT-D (Defibrillator) in all registered patients</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of CRT Therapy on Left Ventricular Volume at End Diastole</title>
          <description>Determine based on echocardiogram study if CRT therapy improves left ventricular volume at end diastole (LVEDV) between baseline and six months</description>
          <population>Describe 23 patients with data available on LVEDV change</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.9" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of CRT Therapy on Left Ventricular Volume at End Systole</title>
        <description>Determine based on echocardiogram study if CRT therapy improves left ventricular volume at end systole (LVESV) between baseline and six months</description>
        <time_frame>6 months post implant</time_frame>
        <population>Describe changes in LVESV in 23 patients with data available</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D (Defibrillator)</title>
            <description>Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
Three-lead CRT-D (Defibrillator): The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of CRT Therapy on Left Ventricular Volume at End Systole</title>
          <description>Determine based on echocardiogram study if CRT therapy improves left ventricular volume at end systole (LVESV) between baseline and six months</description>
          <population>Describe changes in LVESV in 23 patients with data available</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.0" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in New York Heart Association (NYHA) Functional Class</title>
        <description>Improvement in NYHA functional class between baseline and six months (yes/no), ie. change from NYHA class III to NYHA II.</description>
        <time_frame>6 months post implant</time_frame>
        <population>Improvement in NYHA functional class between baseline and six months (yes/no) in 29 participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D (Defibrillator)</title>
            <description>Implantation of a three-lead CRT-D (Defibrillator) in all registered patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in New York Heart Association (NYHA) Functional Class</title>
          <description>Improvement in NYHA functional class between baseline and six months (yes/no), ie. change from NYHA class III to NYHA II.</description>
          <population>Improvement in NYHA functional class between baseline and six months (yes/no) in 29 participants with data available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Left Atrial Size</title>
        <description>Change in left atrial size between baseline and six months</description>
        <time_frame>6 months post implant</time_frame>
        <population>Change in left atrial size between baseline and six months was analyzed in 26 patients with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D (Defibrillator)</title>
            <description>Implantation of a three-lead CRT-D (Defibrillator) in all registered patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Atrial Size</title>
          <description>Change in left atrial size between baseline and six months</description>
          <population>Change in left atrial size between baseline and six months was analyzed in 26 patients with data available.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effects of CRT on Frequency of Heart Failure</title>
        <description>Effects of CRT on the frequency of heart failure with end point of inpatient hospitalization with augmented treatment for heart failure</description>
        <time_frame>6 months post implant</time_frame>
        <population>Frequency of heart failure described in the study population.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D (Defibrillator)</title>
            <description>Implantation of a three-lead CRT-D (Defibrillator) in all registered patients</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of CRT on Frequency of Heart Failure</title>
          <description>Effects of CRT on the frequency of heart failure with end point of inpatient hospitalization with augmented treatment for heart failure</description>
          <population>Frequency of heart failure described in the study population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>We have collected data on adverse events during the 6 months follow-up in the study.</time_frame>
      <desc>The definition of adverse event and/or serious adverse event is the same as on clinicaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>CRT-D (Defibrillator)</title>
          <description>Implantation of a three-lead CRT-D (Defibrillator) in all registered patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Device Infection</sub_title>
                <description>Device Pocket Infection (&gt;30 days post-implant)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Inappropriate device therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <description>Heart failure event with syncope related to heart failure, hypokalemia, and renal insufficiency</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation/flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The findings are limited by the small sample size, short follow-up, and absence of a control group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Valentina Kutyifa MD, PhD</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-275-2676</phone>
      <email>valentina.kutyifa@heart.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

